Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-17
2007-07-17
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S374000, C514S397000, C514S424000, C514S461000, C548S376100, C548S377100
Reexamination Certificate
active
10628375
ABSTRACT:
The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
REFERENCES:
patent: 5360925 (1994-11-01), Chabrier de Lassauniere et al.
patent: 5607966 (1997-03-01), Hellberg et al.
patent: 5621000 (1997-04-01), Arena et al.
patent: 5700947 (1997-12-01), Del Soldato
patent: 5703073 (1997-12-01), Garvey et al.
patent: 5733909 (1998-03-01), Black et al.
patent: 5780495 (1998-07-01), Del Soldato
patent: 5789413 (1998-08-01), Black et al.
patent: 5811438 (1998-09-01), Helberg et al.
patent: 5849943 (1998-12-01), Atkinson et al.
patent: 5859053 (1999-01-01), Lesur et al.
patent: 5861426 (1999-01-01), Del Soldato et al.
patent: 5925631 (1999-07-01), Black et al.
patent: 6040341 (2000-03-01), Del Soldato et al.
patent: 6043233 (2000-03-01), Garvey et al.
patent: 6046191 (2000-04-01), Hamley et al.
patent: 6048858 (2000-04-01), Garvey et al.
patent: 6051588 (2000-04-01), Garvey et al.
patent: 6057347 (2000-05-01), Garvey et al.
patent: 6083515 (2000-07-01), Garvey et al.
patent: 6143734 (2000-11-01), Garvey et al.
patent: 6248745 (2001-06-01), Hamley et al.
patent: 6297260 (2001-10-01), Bandarage et al.
patent: 6323234 (2001-11-01), Garvey et al.
patent: 6355666 (2002-03-01), Lai et al.
patent: 6365184 (2002-04-01), Depui et al.
patent: 6369260 (2002-04-01), Sannicolo' et al.
patent: 6429223 (2002-08-01), Lai et al.
patent: 6436990 (2002-08-01), Ekwuribe et al.
patent: 6482846 (2002-11-01), Garvey et al.
patent: 6512137 (2003-01-01), Del Soldato et al.
patent: 6525098 (2003-02-01), Ekwuribe et al.
patent: 6552078 (2003-04-01), Ekwuribe et al.
patent: 6593347 (2003-07-01), Bandarage et al.
patent: 2001/0041726 (2001-11-01), Bandarage et al.
patent: 2002/0028845 (2002-03-01), Ekwuribe et al.
patent: 2002/0111370 (2002-08-01), Bergman et al.
patent: 2003/0088111 (2003-05-01), Lai et al.
patent: 0 440 098 (1991-08-01), None
patent: 0 676 204 (1995-10-01), None
patent: 0 656 881 (1998-10-01), None
patent: 0 904 110 (2002-07-01), None
patent: WO 94/03421 (1994-02-01), None
patent: WO 94/04484 (1994-03-01), None
patent: WO 94/12463 (1994-06-01), None
patent: WO 95/09831 (1995-04-01), None
patent: WO 95/30641 (1995-11-01), None
patent: WO 96/13483 (1996-05-01), None
patent: WO 96/32946 (1996-10-01), None
patent: WO 97/16405 (1997-05-01), None
patent: WO 97/28120 (1997-08-01), None
patent: WO 97/28121 (1997-08-01), None
patent: WO 97/31654 (1997-09-01), None
patent: WO 97/36863 (1997-10-01), None
patent: WO 98/09948 (1998-03-01), None
patent: WO 98/25981 (1998-06-01), None
patent: WO 99/44595 (1999-09-01), None
patent: WO 99/45004 (1999-09-01), None
patent: WO 00/00200 (2000-01-01), None
patent: WO 00/06585 (2000-02-01), None
patent: WO 00/25776 (2000-05-01), None
patent: WO 00/44705 (2000-08-01), None
patent: WO 00/51988 (2000-09-01), None
patent: WO 00/61537 (2000-10-01), None
patent: WO 00/61541 (2000-10-01), None
patent: WO 00/61549 (2000-10-01), None
patent: WO 00/61604 (2000-10-01), None
patent: WO 00/72838 (2000-12-01), None
patent: WO 01/00563 (2001-01-01), None
patent: WO 01/04082 (2001-01-01), None
patent: 01/12621 (2001-02-01), None
patent: WO 01/10814 (2001-02-01), None
patent: WO 01/12584 (2001-02-01), None
patent: WO 01/49275 (2001-07-01), None
patent: WO 01/66088 (2001-09-01), None
patent: WO 01/78781 (2001-10-01), None
patent: WO 01/87343 (2001-11-01), None
patent: WO 01/93680 (2001-12-01), None
patent: WO 02/00166 (2002-01-01), None
patent: WO 02/00167 (2002-01-01), None
patent: WO 02/11706 (2002-02-01), None
patent: WO 02/11707 (2002-02-01), None
patent: WO 02/30866 (2002-04-01), None
patent: WO 02/051385 (2002-07-01), None
patent: WO 02/053188 (2002-07-01), None
patent: WO 02/092072 (2002-11-01), None
patent: WO 02/100400 (2002-12-01), None
patent: WO 03/000642 (2003-01-01), None
patent: WO 03/000643 (2003-01-01), None
patent: WO 03/022249 (2003-03-01), None
Gu, Qu-Ming, Ching-Shih Chen and C. J. Sih. 1986. “A Facile Enzymatic Resolution Process for the Preparation of (+)-S-2-(6-Methoxy-2-Naphthyl) Propionic Acid (Naproxen).”Tetrahedron Letters, vol. 27, No. 16. pp. 1763-1766.
Palmer, R. M. J., D. S. Ashton and S. Moncada. Jun. 16, 1988. “Vascular endothelial cells synthesize nitric oxide from L-arginine.”Nature, vol. 333. pp. 664-666.
MacNaughton, Wallace K., Giuseppe Cirino and John L. Wallace. Sep. 5, 1989. “Endothelium-Derived Relaxing Factor (Nitric Oxide) Has Protective Actions in the Stomach.”Life Sciences, vol. 45. pp. 1869-1876.
Kitagawa, Hisato, Fumiyo Takeda and Hiroshi Kohei. Mar. 15, 1990. “Effect of Endothelium-Derived Relaxing Factor on The Gastric Lesion Induced by HCI in Rats.”The Journal of Pharmacology and Experimental Therapeutics, vol. 253, No. 3. pp. 1133-1137.
Boughton-Smith, Nigel K., Iain R. Hutcheson, Angela M. Deakin, Brendan J. R. Whittle and S. Moncada. Oct. 23, 1990. “Protective effect of S-nitroso-N-acetyl-penicillamine in endotoxin-induced acute intestinal damage in the rat.”European Journal of Pharmacology, vol. 191. pp. 485-488.
Brown, James F., Peter J. Hanson, and Brendan J. R. Whittle. Oct. 13, 1992. “Nitric oxide donors increase mucus gel thickness in rat stomach.”European Journal of Pharmacology, vol. 223. pp. 103-104.
Conforti, A., M. Donini, G. Brocco, P. Del Soldato, G. Benoni, and L. Cuzzolin. 1993. “Acute anti-inflammatory activity and gastrointestinal tolerability of diclofenac and nitrofenac.”Agents Actions, vol. 40. pp. 176-180.
Reuter, B. K., G. W. McKnight, G. Cirino and J. L. Wallace. 1993. “Nitric Oxide Releasing Nsaid Derivatives Do Not Cause Intestinal Injury or Exacerbate Pre-Existing Colitis.”Castagliuolo I et al. Gastroenterology, vol. 104, No. A678.
Konturek, Stanislaw J., Tomasz Brzozowski, Jolanta Majka, Jolanta Pytko-Polonczyk and Jerzy Stachura. Jun. 1, 1993. “Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers.”European Journal of Pharmacology, vol. 239. pp. 215-217.
Carty, Thomas J.. 1993. “Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam.”Agents Actions, vol. 39. pp. 158-165.
Cuzzolin, Laura et al.. 1994. “Effects on Intestinal Microflora, Gastrointestinal Tolerability and Antiinflammatory Efficacy of Diclofenac and Nitrofenac in Adjuvant Arthritic Rats.”Pharmacological Research, vol. 29, No. 1. pp. 89-97.
Rachmilewitz, D. et al. 1994. “Enhanced gastric nitric oxide synthase activity in duodenal ulcer patients.”Gut, vol. 35. pp. 1394-1397.
Wallace, John L. et al. Mar. 8, 1994. “A diclofenac derivative without ulcerogenic properties.”European Journal of Pharmacology, vol. 257. pp. 249-255.
Reuter, Brian K., Giuseppe Cirino and John L. Wallace. Apr. 18, 1994. “Markedly Reduced Intestinal Toxicity of a Diclofenac Derivative.”Life Sciences, vol. 55, No. 1. pp. PL-1-PL-8.
Wallace, John L. and Giuseppe Cirino. 1
Garvey David S.
Khanapure Subhash P.
Ranatunge Ramani R.
Richardson Stewart K.
Schroeder Joseph D.
NitroMed Inc.
Saeed Kamal A.
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Cyclooxygenase-2 selective inhibitors, compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclooxygenase-2 selective inhibitors, compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclooxygenase-2 selective inhibitors, compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3797053